Education
About Us
Working with TipRanks
Follow Us
VolitionRX (VNRX)
:VNRX
VNRX Stock Chart & Stats
$0.20
$0.01(1.52%)
At close: 4:00 PM EST
$0.20
$0.01(1.52%)
Day’s Range― - ―
52-Week Range$0.17 - $0.94
Previous CloseN/A
Volume29.92K
Average Volume (3M)1.94M
Market Cap
$26.68M
Enterprise Value$30.68M
Total Cash (Recent Filing)$199.41K
Total Debt (Recent Filing)$11.26M
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Mar 31, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding135,565,320
10 Day Avg. Volume2,122,974
30 Day Avg. Volume1,938,813
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-2.08
Price to Sales (P/S)42.09
P/FCF Ratio-1.96
Enterprise Value/Market Cap1.15
Enterprise Value/Revenue20.84
Enterprise Value/Gross Profit20.84
Enterprise Value/Ebitda-1.51
Forecast
1Y Price Target
$3.00Price Target Upside1400.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.1
Revenue Forecast (FY)$9.19M
Bulls Say, Bears Say
Bulls Say
Clinical PerformanceStrong clinical evidence that H3.1 levels outperform standard ICU severity scores could accelerate hospital adoption of the company's assays and increase commercial uptake.
Commercial Expansion And Licensing UpsideCommercialization of Nu.Q Vet Feline and clinical certification sales of Nu.Q Cancer assays could expand revenue beyond veterinary products and provide upside to analyst models.
Government-backed ValidationInclusion of Nu.Q NETs in France's real-world sepsis evaluation and financing for the DETECSEPS consortium enhances clinical credibility and supports broader market acceptance.
Bears Say
Balance Sheet And Financing RiskLow cash balances, high cash burn, and negative shareholders' equity create a financing overhang that could necessitate dilutive capital raises and pressure the stock.
Clinical And Licensing Execution RiskFailure in clinical development of diagnostic products or inability to secure license agreements would materially impede product commercialization and revenue growth.
Research Independence RiskThird-party research provider relationships with covered companies may create conflicts of interest that undermine report objectivity and investor trust.
VolitionRX News
VNRX FAQ
What was VolitionRX’s price range in the past 12 months?
VolitionRX lowest stock price was $0.17 and its highest was $0.94 in the past 12 months.
What is VolitionRX’s market cap?
VolitionRX’s market cap is $26.68M.
When is VolitionRX’s upcoming earnings report date?
VolitionRX’s upcoming earnings report date is Mar 31, 2026 which is in 25 days.
How were VolitionRX’s earnings last quarter?
VolitionRX released its earnings results on Nov 13, 2025. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of -$0.044 by -$0.006.
Is VolitionRX overvalued?
According to Wall Street analysts VolitionRX’s price is currently Undervalued.
Does VolitionRX pay dividends?
VolitionRX does not currently pay dividends.
What is VolitionRX’s EPS estimate?
VolitionRX’s EPS estimate is -0.04.
How many shares outstanding does VolitionRX have?
VolitionRX has 135,565,320 shares outstanding.
What happened to VolitionRX’s price movement after its last earnings report?
VolitionRX reported an EPS of -$0.05 in its last earnings report, missing expectations of -$0.044. Following the earnings report the stock price went down -6.497%.
Which hedge fund is a major shareholder of VolitionRX?
Currently, no hedge funds are holding shares in VNRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
VolitionRX
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
VNRX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in revenue growth, cost management, and strategic partnerships with major companies like Werfen and Hologic. Scientific advancements also promise future potential. However, challenges remain, such as unpredictable revenue and uncertainty in closing additional licensing agreements.View all VNRX earnings summariesVNRX Stock 12 Month Forecast
Average Price Target
$3.00
▲(1400.00% Upside)
Technical Analysis
Ownership Overview
9.83% Insiders
1.29% Mutual Funds
0.26% Other Institutional Investors
87.87% Public Companies and
Individual Investors